Biological Response Modifiers: Their Potential and Limitations in Cancer Therapeutics

References

• Mihich E. Chemotherapy and immunotherapy as a combined modality of cancer treatment. International Congress Series, No. 420, Advances in Tumour Prevention, Detection and Characterization, Volume 4, Characterization and Treatment of Human Tumours, W Davis, K R Harrap. Excerpta Medica, Amsterdam 1978; 113–121
   Google Scholar
• Mastrangelo M J, Berd D, Maguire H C. Current condition and prognosis of tumor immunotherapy: A second opinion. Cancer Treat Rep 1984; 68: 207–219
   PubMedGoogle Scholar
• Report on the Biological Response Modifiers by the Subcommittee of the DCT Board of Scientific Advisers. E Mihich, A Fefer, 1983, J Natl Cancer Inst Monogr No 63
   Google Scholar
• Bloch A. Induced cell differentiation in cancer therapy. Cancer Treat Rep 1984; 68: 199–205
   PubMedGoogle Scholar
• Mihich E. Biological response modifiers in cancer therapeutics. Cancer: Achievements, Challenges and Prospects for the 1980′s, J H Burchenal, H F Oettgen. Grune and Stratton, New York 1981; Vol 2: 135–146
   Google Scholar
• Borden E C, Edwards B S, Hawkins M J, . Interferons: Biological response modification and pharmacology. Biological Response in Cancer: Progress Toward Potential Applications, E Mihich, et al. Plenum Press, New York 1982; Vol 1: 169–218
   Google Scholar
• Doyle A, Gazdar A, Martin J, et al. The deficit in HLA expression in small cell lung cancer (SCLC) resides at the transcriptional level and is reversed by interferon. Proc Am Soc Clin Oncol 1984; 3: 52
   Google Scholar
• Kirkwood J M, Ernstoff M S. Interferons in the treatment of human cancer. J Clin Oncol 1984; 2: 336–352
   PubMed Web of Science ®Google Scholar
• Oldham R K. Biologicals and biological response modifiers: Fourth modality of cancer treatment. Cancer Treat Rep 1984; 68: 207–219
   PubMedGoogle Scholar
• Johnson H M. Modulation of the immune response by interferons and their inducers. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley and Sons, New York 1982; 241–256
   Google Scholar
• Mizel S B. The interleukins: Regulation of lymphocyte differentiation, proliferation, and functional activation. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich. Plenum Press, New York 1982; Vol 1: 89–119
   Google Scholar
• Ruscetti F, Mier J, Gootenberg J, Gallo R. The interaction of human T-cell growth factor with normal and neoplastic T cells. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich. Plenum Press, New York 1982; Vol 1: 121–168
   Google Scholar
• Cheever M A, Greenberg P D, Fefer A. Lymphocyte transfer for cancer therapy: Prerequisites for efficacy and the use of long-term cultured T lymphocytes. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich. Plenum Press, New York 1984; Vol 2: 145–183
   Google Scholar
• Vitetta E S, Uhr J W. The potential use of immunotoxins in transplantation, cancer therapy, and immunoregulation. Transplantation 1984; 37: 535–538
   PubMed Web of Science ®Google Scholar
• Miller R A, Levy R. Response of cutaneous T cell lymphomas to therapy with hybridoma monoclonal antibody. Lancet 1981; 2: 226–280
   PubMed Web of Science ®Google Scholar
• Ritz J, Schlossman S F. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 1982; 59: 1–11
   PubMed Web of Science ®Google Scholar
• Goldstein A L, Low T LK, Thurman G B, . Thymosins and other hormone-like factors of the thymus gland. Immunological Approaches to Cancer Therapeutics, E Mihich, et al. John Wiley and Sons, New York 1982; 137–190
   Google Scholar
• Smalley R V, Talmadge J, Oldham R K, et al. The thymosins— Preclinical and clinical studies with fraction V and alpha. I. Cancer Treat Rev 1984; 11: 69–84
   PubMed Web of Science ®Google Scholar
• Fefer A, Cheever M A, Greenberg P D. Lymphocyte transfer as potential cancer immunotherapy. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley and Sons, New York 1982; 333–362
   Google Scholar
• Bernstein I D, Nowinski R C, Wright P W. Monoclonal antibodies: Prospects for cancer treatment. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley and Sons, New York 1982; 277–297
   Google Scholar
• Hammersmith Oncology Group and Imperial Cancer Research Fund Royal Postgraduate Medical School and Hammersmith Hospital, London) Courtenay-Luck, Epenetos A A, Hainan K E, et al. Antibody-guided irradiation of malignant lesions: Three cases illustrating a new method of treatment. Lancet 1984; 1: 1441–1443
   PubMed Web of Science ®Google Scholar
• Order S E, Klein J, Leichner P. radiolabelled antibody (antiferritin) in the treatment of hepatmoma—An update. Proc Am Soc Clin Oncol 1984; 3: 138
   Google Scholar
• Rosenberg S A, Terry W D. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977; 25: 233–288
   Google Scholar
• Bast R C, Jr, Ritz J. Application of monoclonal antibodies to autologous bone marrow transplantation. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich. Plenum Press, New York 1984; Vol 2: 185–206
   Google Scholar
• Miller R A, Maloney D G, Warnicki E R, et al. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med 1982; 306: 517–522
   PubMed Web of Science ®Google Scholar
• Lowder J N, Meeker T C, Maloney D G, et al. Anti-idiotype monoclonal antibody therapy of human B lymphocytic malignancy. Proc Am Soc Clin Oncol 1984; 3: 250
   Google Scholar
• Oldham R K. Monoclonal antibodies in cancer therapy. J Clin Oncol 1983; 1: 582–590
   PubMed Web of Science ®Google Scholar
• Alexander P. The role of macrophages in tumor immunity. J Clin Path 1974; 27(Suppl 7)77–82
   Google Scholar
• Mastrangelo M J, Berd D, Bellet R E. Critical review of previous reported clinical trials of cancer immunotherapy with nonspecific immunostimulants. Ann NY Acad Sci 1976; 277: 94–123
   PubMed Web of Science ®Google Scholar
• Fidler I J, Berendt M J. The biological diversity of malignant neoplasms. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich. Plenum Press, New York 1982; Vol 1: 269–299
   Google Scholar
• Lederer E, Chedid L. Immunomodulation by synthetic muramyl peptides and trehalose diesters. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley and Sons, New York 1982; 107–135
   Google Scholar
• Dukor P, Tarcsay L, Baschang G. Immunostimulants. Annu Rep Med Chem 1979; 14: 146–167
   Google Scholar
• Mantovani A. Effect of glucocorticoid hormones on the immune system. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich, Y Sakurai. Plenum Press, New York, Vol 3., in press
   Google Scholar
• Herberman R B, Holden H T. Natural cell-mediated immunity. Adv Cancer Res 1978; 27: 305–377
   PubMedGoogle Scholar
• Herberman R B, Santoni A. Regulation of natural killer cell activity. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich. Plenum Press, New York 1984; Vol 2: 121–144
   Google Scholar
• Roder J C, Pross H F. The biology of the human natural killer cell. J Clin Immunol 1982; 2: 249–262
   PubMed Web of Science ®Google Scholar
• Brown J M, Rosenberg S A. Serologic analysis of human solid tumor antigens. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley and Sons, New York 1982; 1–37
   Google Scholar
• Oettgen H F. Host defense against cancer. Cancer: Achievements, Challenges and Prospects for the 1980s, J H Burchenal, H F Oettgen. Grune and Stratton, New York 1981; Vol 2: 309–330
   Google Scholar
• Ritz J, Griffin J D. Cell-surface antigens in acute leukemia. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich. Plenum Press, New York 1982; Vol 1: 1–21
   Google Scholar
• Ozer H. Tumor immunity and escape mechanisms in humans. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley and Sons, New York 1982; 39–73
   Google Scholar
• Mastrangelo M F, Berd D. Immunotherapy with microbial products. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley and Sons, New York 1982; 75–105
   Google Scholar
• Mathe G, Amiel J F, Schwarzenberg I, et al. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969; 1: 697–699
   PubMed Web of Science ®Google Scholar
• Morton D L. Immunological studies with human neoplasms. J Reticuloendothel Soc 1971; 10: 137–160
   PubMedGoogle Scholar
• Klein E, Holtermann O A, Papermaster B, et al. Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives. Natl Cancer Inst Monogr 1973; 39: 229–239
   PubMedGoogle Scholar
• Torti F M, Lum B L. The biology and treatment of superficial bladder cancer. J Clin Oncol 1984; 2: 505–531
   PubMed Web of Science ®Google Scholar
• Wright P W, Hill L D, Peterson A V, et al. Levamisole (L) results in immunosuppression and lacks antitumor activity when combined with intrapleural BCG (Ip-BCG) in patients with resected non-small cell lung cancer. Proc Am Soc Clin Oncol 1980; 21: 452
   Google Scholar
• Holland J F, Bekesi J G. Comparison of chemotherapy with chemotherapy plus VCN-treated cells in acute myelocytic leukemia. Prog Cancer Res Ther 1978; 6: 347–353
   Google Scholar
• Stewart W E. Heterogeneities of human interferons. Biological Responses in Cancer: Progress Toward Potential Applications, E Mihich. Plenum Press, New York 1984; Vol 2: 19–44
   Google Scholar
• Houghton A N, Thomson T M, Gross D, et al. Surface antigens of melanoma and melanocytes. J Exp Med 1984; 160: 255–269
   PubMed Web of Science ®Google Scholar
• Ito M, O'Malley J A, Mirand E A. Synergistic anti-cellular effects of human interferons (IFN) —β and —μg in combinations. Proc Am Assoc Cancer Res 1984; 25: 227
   Web of Science ®Google Scholar
• Chany C, Cerutti I. Antitumor effect of arginine butyrate in conjunction with Corynebacterium parvum and interferon. Int J Cancer 1982; 30: 489–493
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (London) 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Rook A H, Masur H C, Lane C, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983; 72: 398–403
   PubMed Web of Science ®Google Scholar
• Cowens J W, Ozer H, Ehrke M J. Inhibition of the development of suppressor cells in culture by 4-hydroperox-ycyclophosphamide. J Immunol 1984; 132: 95–100
   Web of Science ®Google Scholar
• North R J. The murine antitumor immune response and its therapeutic manipulation. Advances in Immunology, H G Kunkel, F J Dixon. Academic Press, New York 1984; 89–155
   Google Scholar
• Gulati S, Gandola L, Vega R, et al. Chemopurification of bone marrow in vitro and its clinical application. Proc Am Assoc Cancer Res 1984; 25: 201
   Web of Science ®Google Scholar
• Ozer H, Cowens J W, Colvin M, et al. In vitro effects of 4-hydroperoxycyclophosphamide on human regulatory T subset function. I. Selective effects on lymphocyte function in T-B collaboration. J Exp Med 1982; 155: 276–290
   PubMed Web of Science ®Google Scholar
• Hersh E. Perspectives for immunological and biological therapeutic intervention in human cancer. Immunological Approaches to Cancer Therapeutics, E Mihich. John Wiley and Sons, New York 1982; 505–540
   Google Scholar
• North R J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 55: 1063–1074
   Web of Science ®Google Scholar